Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Yearly zoledronic acid in postmenopausal osteoporosis.

Karam R, Camm J, McClung M.

N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5. No abstract available.

PMID:
17703529
2.

Yearly zoledronic acid in postmenopausal osteoporosis.

Poole KE, Kaptoge S, Reeve J.

N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5. No abstract available.

PMID:
17703530
3.

Yearly zoledronic acid in postmenopausal osteoporosis.

de Nijs RN, Westgeest AA.

N Engl J Med. 2007 Aug 16;357(7):711; author reply 714-5. No abstract available.

4.

Yearly zoledronic acid in postmenopausal osteoporosis.

Chang JT.

N Engl J Med. 2007 Aug 16;357(7):713-4; author reply 714-5. No abstract available.

PMID:
17703528
5.

Alendronate and atrial fibrillation.

Cummings SR, Schwartz AV, Black DM.

N Engl J Med. 2007 May 3;356(18):1895-6. No abstract available.

6.

[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].

Ringe JD.

MMW Fortschr Med. 2009 Mar 5;151(10):7. German. No abstract available.

PMID:
19472655
7.

[Osteoporosis and bisphosphonates].

Zuber MA.

Z Rheumatol. 2007 Dec;66(8):713-5. German. No abstract available.

PMID:
17955251
8.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
9.

A once-yearly IV bisphosphonate for osteoporosis.

[No authors listed]

Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90. No abstract available.

PMID:
17975523
10.

[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].

Geusens PP, Lems WF.

Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1445-8. Dutch.

PMID:
17633971
11.

Yearly zoledronic acid in postmenopausal osteoporosis.

Najib MA, Aziz I.

N Engl J Med. 2007 Aug 16;357(7):713; author reply 714-5. No abstract available.

PMID:
17703527
12.

Annual zoledronic acid for osteoporosis.

BMJ Group..

Drug Ther Bull. 2008 Dec;46(12):93-6. Review.

PMID:
19056701
13.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
14.

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.

Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.

Osteoporos Int. 2012 Feb;23(2):625-33. doi: 10.1007/s00198-011-1583-4. Epub 2011 Mar 26.

PMID:
21442459
15.

[Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

Dalle Carbonare L, Bertoldo F, Lo Cascio V.

Reumatismo. 2009 Jan-Mar;61(1):54-64. Italian.

16.

Going on a drug holiday?

Bonnick SL.

J Clin Densitom. 2011 Oct-Dec;14(4):377-83. doi: 10.1016/j.jocd.2011.07.006. No abstract available.

PMID:
22051091
17.

Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.

[No authors listed]

Prescrire Int. 2008 Aug;17(96):143.

PMID:
19480098
18.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial..

N Engl J Med. 2007 May 3;356(18):1809-22.

19.

[FACT study].

Tanaka I, Oshima H.

Nihon Rinsho. 2007 Nov 28;65 Suppl 9:280-5. Review. Japanese. No abstract available.

PMID:
18161120
20.

Zoledronic acid and atrial fibrillation in cancer patients.

Arslan C, Aksoy S, Dizdar O, Dede DS, Harputluoglu H, Altundag K.

Support Care Cancer. 2011 Mar;19(3):425-30. doi: 10.1007/s00520-010-0868-z. Epub 2010 Apr 1.

PMID:
20358384

Supplemental Content

Support Center